HRT Financial’s BioNexus Gene Lab BGLC Stock Holding History

HRT Financial’s Portfolio BGLC Stock Details BGLC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,467	Closed	-$6K	–	2425
2024 Q2	$6K	Sell	1,467 -723	-33%	-$4.06K	﹤0.01%	2027
2024 Q1	$15K	Buy	+2,190	New	+$14.4K	﹤0.01%	2033
2023 Q4	–	Sell	-4,547	Closed	-$38K	–	2322
2023 Q3	$38K	Buy	+4,547	New	+$74K	﹤0.01%	2021

Other funds holding BGLC

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

SRL

Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return

HRT Financial's BGLC Position: Q3 2024 in Review

HRT Financial sold out of BioNexus Gene Lab (BGLC) in Q3 2024, closing a stake of 1,467 shares — an estimated $6K sold.

HRT Financial first reported a position in BGLC in Q3 2023 and held it in 3 quarters. The position peaked at $38K in Q3 2023. 4 funds tracked by Wall St. Rank hold BGLC as of Q3 2024.

HRT Financial reported no remaining BioNexus Gene Lab position as of Q3 2024 after selling out during the quarter.
HRT Financial sold 1,467 BioNexus Gene Lab shares in Q3 2024, an estimated $6K.
HRT Financial first reported a position in BioNexus Gene Lab in Q3 2023 and held it in 3 quarters.
HRT Financial's BioNexus Gene Lab position peaked at $38K in Q3 2023.
4 funds tracked by Wall St. Rank held BioNexus Gene Lab as of Q3 2024.

Based on HRT Financial's 13F filing for Q3 2024, filed 12 Nov 2024.